MX2009004745A - Derivados de 1,2,3-triazol como inhibidores del receptor sigma. - Google Patents

Derivados de 1,2,3-triazol como inhibidores del receptor sigma.

Info

Publication number
MX2009004745A
MX2009004745A MX2009004745A MX2009004745A MX2009004745A MX 2009004745 A MX2009004745 A MX 2009004745A MX 2009004745 A MX2009004745 A MX 2009004745A MX 2009004745 A MX2009004745 A MX 2009004745A MX 2009004745 A MX2009004745 A MX 2009004745A
Authority
MX
Mexico
Prior art keywords
triazole derivatives
sigma receptor
receptor inhibitors
compounds
sigma
Prior art date
Application number
MX2009004745A
Other languages
English (en)
Spanish (es)
Inventor
Alberto Dordal Zueras
Nadine Jagerovic
Cristina Ana Gomez-De La Oliva
Maria Pilar Goya-Laza
Maria Rosa Cuberes-Altisent
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MX2009004745A publication Critical patent/MX2009004745A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2009004745A 2006-11-10 2007-11-07 Derivados de 1,2,3-triazol como inhibidores del receptor sigma. MX2009004745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06380289A EP1921071A1 (en) 2006-11-10 2006-11-10 1,2,3- triazole derivatives as sigma receptor inhibitors
PCT/EP2007/062010 WO2008055933A1 (en) 2006-11-10 2007-11-07 1,2,3-triazole derivatives as sigma receptor inhibitors

Publications (1)

Publication Number Publication Date
MX2009004745A true MX2009004745A (es) 2009-05-22

Family

ID=37963991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004745A MX2009004745A (es) 2006-11-10 2007-11-07 Derivados de 1,2,3-triazol como inhibidores del receptor sigma.

Country Status (12)

Country Link
US (1) US8193223B2 (cg-RX-API-DMAC7.html)
EP (2) EP1921071A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010509281A (cg-RX-API-DMAC7.html)
KR (1) KR20090087032A (cg-RX-API-DMAC7.html)
CN (1) CN101589029A (cg-RX-API-DMAC7.html)
AU (1) AU2007316606A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718586A2 (cg-RX-API-DMAC7.html)
CA (1) CA2668996A1 (cg-RX-API-DMAC7.html)
ES (1) ES2413559T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009004745A (cg-RX-API-DMAC7.html)
RU (1) RU2009122198A (cg-RX-API-DMAC7.html)
WO (1) WO2008055933A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2548878A1 (en) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2752411A1 (en) * 2013-01-07 2014-07-09 Laboratorios Del Dr. Esteve, S.A. 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
EP2792679A1 (en) * 2013-04-19 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Tricyclic triazolic compounds
US9963453B2 (en) 2013-04-23 2018-05-08 Laboratorios Del Dr. Esteve S.A. Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators
US9879015B2 (en) 2013-04-23 2018-01-30 Laboratorios Del Dr. Esteve S.A. Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
EP2832720A1 (en) 2013-07-30 2015-02-04 Laboratorios Del. Dr. Esteve, S.A. 1,2-disubstituted cyclobutyl compounds
MX2016007285A (es) 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de inhibidores de la captacion de serotonina-norepinefrina (irsn) y ligandos de receptores sigma.
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
MX378932B (es) 2015-01-30 2025-03-10 Neurocrine Biosciences Inc Triazoles sustituidos y métodos relacionados a estos.
CN106866555B (zh) * 2017-02-08 2019-04-30 东南大学 1-二苯甲基-4-甲基哌嗪类化合物其制备方法和应用
WO2020123847A1 (en) * 2018-12-12 2020-06-18 Rutgers, The State University Of New Jersey Organic compounds
CN116178286B (zh) * 2021-11-26 2024-12-03 华东师范大学 一种n2烷基取代的三氮唑衍生物及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
AU2002224478A1 (en) * 2000-11-02 2002-05-15 K And K Biosciences, Inc. Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke
EP1954128A4 (en) * 2005-11-04 2010-09-22 Merck Sharp & Dohme DIPHENYLMETHANE DERIVATIVES AS AN INHIBITORS OF THE LEUKOTRIEN BIOSYNTHESIS

Also Published As

Publication number Publication date
CA2668996A1 (en) 2008-05-15
EP1921071A1 (en) 2008-05-14
KR20090087032A (ko) 2009-08-14
US20100004265A1 (en) 2010-01-07
EP2097392A1 (en) 2009-09-09
CN101589029A (zh) 2009-11-25
US8193223B2 (en) 2012-06-05
EP2097392B1 (en) 2013-03-13
WO2008055933A1 (en) 2008-05-15
AU2007316606A1 (en) 2008-05-15
BRPI0718586A2 (pt) 2014-03-11
ES2413559T3 (es) 2013-07-16
RU2009122198A (ru) 2010-12-20
JP2010509281A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
ATE520668T1 (de) Sigmarezeptor-inhibitoren
MX2009009153A (es) Pirano-pirazol-aminas.
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
MX2009013321A (es) Derivados de espiro[piperidin-4,4'-tieno[3,2-c]pirano] y compuestos relacionados como inhibidores del receptor sigma para el tratamiento de psicosis.
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200714604A (en) Substituted heterocycles and the uses thereof
GB0625648D0 (en) Compounds
IL197080A0 (en) Pyrimidone compounds as gsk-3 inhibitors
UA105911C2 (uk) Сульфонамідні похідні
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
NZ577916A (en) Cyclopamine analogs
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MX2009011816A (es) Derivados de piridina.
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
AU2009282962A8 (en) Compounds as kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
GEP20135806B (en) Lactams as beta secretase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal